By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Proclara Biosciences (Formerly known as NeuroPhage) 

222 Third Street
Suite 3120
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-941-7020 Fax: 617-941-7021


SEARCH JOBS

Proclara Biosciences is pioneering powerful new methods for treating neurodegenerative diseases long thought to be intractable. We seek talented and ambitious individuals who share our passion for innovative science and our commitment to transforming the lives of patients suffering from serious protein misfolding diseases.

YEAR FOUNDED:

2006

LEADERSHIP:

CEO: Franz Heft

CSO: Richard Fisher

JOBS:

Please click here for Proclara job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@neurophage.com
Ownership: Private

Web Site: Proclara
Employees:
Symbol: 
 



Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Proclara Presents New Preclinical Data Supporting The Development Of NPT189 At Alzheimer’s Association International Conference (AAIC) 2017 7/18/2017 7:26:08 AM
Proclara Announces Pipeline Progress 7/17/2017 6:38:03 AM
Exec Who Orchestrated Promedior's $1.25 Billion Buyout Deal From Bristol-Myers Squibb (BMY) To Helm Proclara 4/26/2017 8:09:10 AM
Proclara Biosciences Australia, A Subsidiary Of Proclara, Awarded Grant By Biopharmaceuticals Australia To Help Develop New Biotherapy With Blockbuster Potential 3/10/2017 6:16:02 AM
Proclara Awarded Part The Cloud Grant From Alzheimer’s Association To Support Development Of NPT088 For Alzheimer’s Disease 11/18/2016 7:43:03 AM
Proclara Announces Newly Issued U.S. Patents For Its Core Technology Targeting Protein Misfolding Disorders 11/16/2016 8:30:22 AM
Proclara Announces Initiation Of Phase Ib Clinical Trial Of NPT088 For Alzheimer’s Disease 9/7/2016 11:39:39 AM
NeuroPhage Transforms Into Proclara, Bags $47 Million and and Launches Phase Ib Alzheimer’s Trial 9/7/2016 5:45:37 AM
NeuroPhage Pharmaceuticals, Inc.'s NPT088 Universally Targets Misfolded Proteins In Preclinical Studies Highlighted In Oral Session At The Alzheimer's Association International Conference 7/20/2015 8:01:14 AM
NeuroPhage Pharmaceuticals, Inc. To Be Featured In Oral Session At The 2015 Alzheimer's Association International Conference 7/13/2015 7:35:01 AM
123
//-->